Cargando…

KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment

BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Normanno, Nicola, Pinto, Carmine, Castiglione, Francesca, Bardelli, Alberto, Gambacorta, Marcello, Botti, Gerardo, Nappi, Oscar, Siena, Salvatore, Ciardiello, Fortunato, Taddei, GianLuigi, Marchetti, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244430/
https://www.ncbi.nlm.nih.gov/pubmed/22216189
http://dx.doi.org/10.1371/journal.pone.0029146
_version_ 1782219730373836800
author Normanno, Nicola
Pinto, Carmine
Castiglione, Francesca
Bardelli, Alberto
Gambacorta, Marcello
Botti, Gerardo
Nappi, Oscar
Siena, Salvatore
Ciardiello, Fortunato
Taddei, GianLuigi
Marchetti, Antonio
author_facet Normanno, Nicola
Pinto, Carmine
Castiglione, Francesca
Bardelli, Alberto
Gambacorta, Marcello
Botti, Gerardo
Nappi, Oscar
Siena, Salvatore
Ciardiello, Fortunato
Taddei, GianLuigi
Marchetti, Antonio
author_sort Normanno, Nicola
collection PubMed
description BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate therapy for these patients. METHODOLOGY/PRINCIPAL FINDINGS: In order to guarantee the possibility for mCRC patients to receive an high quality KRAS testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology -Italian division of the International Academy of Pathology (SIAPEC-IAP) started a program to improve KRAS testing. AIOM and SIAPEC identified a large panel of Italian medical oncologists, pathologists and molecular biologists that outlined guidelines for KRAS testing in mCRC patients. These guidelines include specific information on the target patient population, the biological material for molecular analysis, the extraction of DNA, and the methods for the mutational analysis that are summarized in this paper. Following the publication of the guidelines, the scientific societies started an external quality assessment scheme for KRAS testing. Five CRC specimens with known KRAS mutation status were sent to the 59 centers that participated to the program. The samples were validated by three referral laboratories. The participating laboratories were allowed to use their own preferred method for DNA extraction and mutational analysis and were asked to report the results within 4 weeks. The limit to pass the quality assessment was set at 100% of true responses. In the first round, only two centers did not pass (3%). The two centers were offered to participate to a second round and both centers failed again to pass. CONCLUSIONS: The results of this first Italian quality assessment for KRAS testing suggest that KRAS mutational analysis is performed with good quality in the majority of Italian centers.
format Online
Article
Text
id pubmed-3244430
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32444302012-01-03 KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment Normanno, Nicola Pinto, Carmine Castiglione, Francesca Bardelli, Alberto Gambacorta, Marcello Botti, Gerardo Nappi, Oscar Siena, Salvatore Ciardiello, Fortunato Taddei, GianLuigi Marchetti, Antonio PLoS One Research Article BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate therapy for these patients. METHODOLOGY/PRINCIPAL FINDINGS: In order to guarantee the possibility for mCRC patients to receive an high quality KRAS testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology -Italian division of the International Academy of Pathology (SIAPEC-IAP) started a program to improve KRAS testing. AIOM and SIAPEC identified a large panel of Italian medical oncologists, pathologists and molecular biologists that outlined guidelines for KRAS testing in mCRC patients. These guidelines include specific information on the target patient population, the biological material for molecular analysis, the extraction of DNA, and the methods for the mutational analysis that are summarized in this paper. Following the publication of the guidelines, the scientific societies started an external quality assessment scheme for KRAS testing. Five CRC specimens with known KRAS mutation status were sent to the 59 centers that participated to the program. The samples were validated by three referral laboratories. The participating laboratories were allowed to use their own preferred method for DNA extraction and mutational analysis and were asked to report the results within 4 weeks. The limit to pass the quality assessment was set at 100% of true responses. In the first round, only two centers did not pass (3%). The two centers were offered to participate to a second round and both centers failed again to pass. CONCLUSIONS: The results of this first Italian quality assessment for KRAS testing suggest that KRAS mutational analysis is performed with good quality in the majority of Italian centers. Public Library of Science 2011-12-21 /pmc/articles/PMC3244430/ /pubmed/22216189 http://dx.doi.org/10.1371/journal.pone.0029146 Text en Normanno et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Normanno, Nicola
Pinto, Carmine
Castiglione, Francesca
Bardelli, Alberto
Gambacorta, Marcello
Botti, Gerardo
Nappi, Oscar
Siena, Salvatore
Ciardiello, Fortunato
Taddei, GianLuigi
Marchetti, Antonio
KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
title KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
title_full KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
title_fullStr KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
title_full_unstemmed KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
title_short KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
title_sort kras mutations testing in colorectal carcinoma patients in italy: from guidelines to external quality assessment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244430/
https://www.ncbi.nlm.nih.gov/pubmed/22216189
http://dx.doi.org/10.1371/journal.pone.0029146
work_keys_str_mv AT normannonicola krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment
AT pintocarmine krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment
AT castiglionefrancesca krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment
AT bardellialberto krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment
AT gambacortamarcello krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment
AT bottigerardo krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment
AT nappioscar krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment
AT sienasalvatore krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment
AT ciardiellofortunato krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment
AT taddeigianluigi krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment
AT marchettiantonio krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment